This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Report on the Efficacy and Toxicity of Long-Term Intermittent Treatment

Charles J. McDonald, MD; Joseph R. Bertino, MD

Arch Dermatol. 1969;100(6):655-668.

Abstract
Thirty-six patients with severe, debilitating, and refractory psoriasis, arthritis, or both were treated with parenteral methotrexate for periods of time that varied from six months to three years. Five of the 36 patients had previously received oral methotrexate without adequate control of the disease.

Of the patients, 80% responded to 25 and 50 mg of the drug biweekly. The remaining 20% could be controlled with 75 mg biweekly, however, the incidence of drug-induced toxicity increased significantly with the higher drug dosages, but was not severe enough to cause permanent cessation of therapy.

Data obtained were compared with data presented by other investigators using the oral and parenteral routes. The regimen of 25 to 50 mg of biweekly parenteral methotrexate gave therapeutic results comparable to those reported by others using higher parenteral and daily oral dosages. Knowledge of the pharmacology of methotrexate leads one to believe that the use of this regimen will reduce the potential for long-term toxicity.

Author Affiliations
New Haven, Conn

From the Department of Medicine and Pharmacology, Yale University School of Medicine, New Haven, Conn. Dr. McDonald is currently at the Division of Bio-Medical Science, Brown University, Providence, RI.

Footnotes
Accepted for publication July 29, 1969.

Reprint requests to Division of Bio-Medical Science, Brown University, Roger Williams General Hospital, Providence, RI 02908 (Dr. McDonald).

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

An Appraisal of Current Systemic Chemotherapy for Psoriasis
Farber et al.
Arch Dermatol 1976;112:1679-1688.
ABSTRACT  

Immunosuppressive and Cytotoxic Drugs in Dermatology
Dantzig
Arch Dermatol 1974;110:393-406.
ABSTRACT  

Liver Disease Associated With Methotrexate Treatment of Psoriatic Patients
Dubin and Harrell
Arch Dermatol 1970;102:498-503.
ABSTRACT  

Failure of Leucovorin "Rescue" in Methotrexate Treatment of Psoriasis
Cipriano et al.
Arch Dermatol 1970;101:651-652.
ABSTRACT